Treatment of membranous lupus nephritis

Gabriella Moroni, Massimo Maccario, Giovanni Banfi, Silvana Quaglini, Claudio Ponticelli

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

In this study, we retrospectively analyzed the effects of treatment in 19 patients with membranous lupus nephritis (MLN) and nephrotic syndrome. Eight patients were treated with corticosteroids alone, and the other 11 patients received methylprednisolone and chlorambucil alternated every other month for 6 months. At presentation, sex, age, duration of renal disease before renal biopsy, plasma creatinine, and arterial hypertension were similar in the two study groups. Of the eight patients treated with corticosteroids alone, three showed complete remission and one partial remission of the nephrotic syndrome. During the follow-up (mean, 114 ± 63 months), seven of these eight patients developed one or more renal flare- ups. Of the 11 patients treated with methylprednisolone and chlorambucil, seven had complete remission, and the other four had partial remission of the nephrotic syndrome. During the follow-up (mean, 83 ± 59 months), only one patient had renal flare-up. At the end of the follow-up, all patients were alive, but three patients in the group treated with corticosteroids alone had developed a doubling of plasma creatinine, and another patient had persistent nephrotic syndrome. Two other patients were in complete remission, one patient was in partial remission, and the last patient had nonnephrotic proteinuria. In the group of patients treated with methylprednisolone and chlorambucil, one patient developed extracapillary glomerulonephritis and eventually entered end-stage renal failure 24 years after the clinical onset of renal disease. Seven patients were in complete remission, and three patients were in partial remission at the last follow-up visit. This retrospective study suggests that methylprednisolone and chlorambucil may induce a more stable remission of nephrotic syndrome and may better protect renal function in the long term in comparison with corticosteroids alone. However, these results must he confirmed by a prospective controlled trial.

Original languageEnglish
Pages (from-to)681-686
Number of pages6
JournalAmerican Journal of Kidney Diseases
Volume31
Issue number4
Publication statusPublished - Apr 1998

Fingerprint

Lupus Nephritis
Nephrotic Syndrome
Chlorambucil
Therapeutics
Methylprednisolone
Kidney
Adrenal Cortex Hormones
Creatinine

Keywords

  • Corticosteroids
  • Immunosuppressive therapy
  • Nephritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Nephrology

Cite this

Moroni, G., Maccario, M., Banfi, G., Quaglini, S., & Ponticelli, C. (1998). Treatment of membranous lupus nephritis. American Journal of Kidney Diseases, 31(4), 681-686.

Treatment of membranous lupus nephritis. / Moroni, Gabriella; Maccario, Massimo; Banfi, Giovanni; Quaglini, Silvana; Ponticelli, Claudio.

In: American Journal of Kidney Diseases, Vol. 31, No. 4, 04.1998, p. 681-686.

Research output: Contribution to journalArticle

Moroni, G, Maccario, M, Banfi, G, Quaglini, S & Ponticelli, C 1998, 'Treatment of membranous lupus nephritis', American Journal of Kidney Diseases, vol. 31, no. 4, pp. 681-686.
Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. American Journal of Kidney Diseases. 1998 Apr;31(4):681-686.
Moroni, Gabriella ; Maccario, Massimo ; Banfi, Giovanni ; Quaglini, Silvana ; Ponticelli, Claudio. / Treatment of membranous lupus nephritis. In: American Journal of Kidney Diseases. 1998 ; Vol. 31, No. 4. pp. 681-686.
@article{44cb8d48cebe4e93b1f57580cbe2909c,
title = "Treatment of membranous lupus nephritis",
abstract = "In this study, we retrospectively analyzed the effects of treatment in 19 patients with membranous lupus nephritis (MLN) and nephrotic syndrome. Eight patients were treated with corticosteroids alone, and the other 11 patients received methylprednisolone and chlorambucil alternated every other month for 6 months. At presentation, sex, age, duration of renal disease before renal biopsy, plasma creatinine, and arterial hypertension were similar in the two study groups. Of the eight patients treated with corticosteroids alone, three showed complete remission and one partial remission of the nephrotic syndrome. During the follow-up (mean, 114 ± 63 months), seven of these eight patients developed one or more renal flare- ups. Of the 11 patients treated with methylprednisolone and chlorambucil, seven had complete remission, and the other four had partial remission of the nephrotic syndrome. During the follow-up (mean, 83 ± 59 months), only one patient had renal flare-up. At the end of the follow-up, all patients were alive, but three patients in the group treated with corticosteroids alone had developed a doubling of plasma creatinine, and another patient had persistent nephrotic syndrome. Two other patients were in complete remission, one patient was in partial remission, and the last patient had nonnephrotic proteinuria. In the group of patients treated with methylprednisolone and chlorambucil, one patient developed extracapillary glomerulonephritis and eventually entered end-stage renal failure 24 years after the clinical onset of renal disease. Seven patients were in complete remission, and three patients were in partial remission at the last follow-up visit. This retrospective study suggests that methylprednisolone and chlorambucil may induce a more stable remission of nephrotic syndrome and may better protect renal function in the long term in comparison with corticosteroids alone. However, these results must he confirmed by a prospective controlled trial.",
keywords = "Corticosteroids, Immunosuppressive therapy, Nephritis, Systemic lupus erythematosus",
author = "Gabriella Moroni and Massimo Maccario and Giovanni Banfi and Silvana Quaglini and Claudio Ponticelli",
year = "1998",
month = "4",
language = "English",
volume = "31",
pages = "681--686",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Treatment of membranous lupus nephritis

AU - Moroni, Gabriella

AU - Maccario, Massimo

AU - Banfi, Giovanni

AU - Quaglini, Silvana

AU - Ponticelli, Claudio

PY - 1998/4

Y1 - 1998/4

N2 - In this study, we retrospectively analyzed the effects of treatment in 19 patients with membranous lupus nephritis (MLN) and nephrotic syndrome. Eight patients were treated with corticosteroids alone, and the other 11 patients received methylprednisolone and chlorambucil alternated every other month for 6 months. At presentation, sex, age, duration of renal disease before renal biopsy, plasma creatinine, and arterial hypertension were similar in the two study groups. Of the eight patients treated with corticosteroids alone, three showed complete remission and one partial remission of the nephrotic syndrome. During the follow-up (mean, 114 ± 63 months), seven of these eight patients developed one or more renal flare- ups. Of the 11 patients treated with methylprednisolone and chlorambucil, seven had complete remission, and the other four had partial remission of the nephrotic syndrome. During the follow-up (mean, 83 ± 59 months), only one patient had renal flare-up. At the end of the follow-up, all patients were alive, but three patients in the group treated with corticosteroids alone had developed a doubling of plasma creatinine, and another patient had persistent nephrotic syndrome. Two other patients were in complete remission, one patient was in partial remission, and the last patient had nonnephrotic proteinuria. In the group of patients treated with methylprednisolone and chlorambucil, one patient developed extracapillary glomerulonephritis and eventually entered end-stage renal failure 24 years after the clinical onset of renal disease. Seven patients were in complete remission, and three patients were in partial remission at the last follow-up visit. This retrospective study suggests that methylprednisolone and chlorambucil may induce a more stable remission of nephrotic syndrome and may better protect renal function in the long term in comparison with corticosteroids alone. However, these results must he confirmed by a prospective controlled trial.

AB - In this study, we retrospectively analyzed the effects of treatment in 19 patients with membranous lupus nephritis (MLN) and nephrotic syndrome. Eight patients were treated with corticosteroids alone, and the other 11 patients received methylprednisolone and chlorambucil alternated every other month for 6 months. At presentation, sex, age, duration of renal disease before renal biopsy, plasma creatinine, and arterial hypertension were similar in the two study groups. Of the eight patients treated with corticosteroids alone, three showed complete remission and one partial remission of the nephrotic syndrome. During the follow-up (mean, 114 ± 63 months), seven of these eight patients developed one or more renal flare- ups. Of the 11 patients treated with methylprednisolone and chlorambucil, seven had complete remission, and the other four had partial remission of the nephrotic syndrome. During the follow-up (mean, 83 ± 59 months), only one patient had renal flare-up. At the end of the follow-up, all patients were alive, but three patients in the group treated with corticosteroids alone had developed a doubling of plasma creatinine, and another patient had persistent nephrotic syndrome. Two other patients were in complete remission, one patient was in partial remission, and the last patient had nonnephrotic proteinuria. In the group of patients treated with methylprednisolone and chlorambucil, one patient developed extracapillary glomerulonephritis and eventually entered end-stage renal failure 24 years after the clinical onset of renal disease. Seven patients were in complete remission, and three patients were in partial remission at the last follow-up visit. This retrospective study suggests that methylprednisolone and chlorambucil may induce a more stable remission of nephrotic syndrome and may better protect renal function in the long term in comparison with corticosteroids alone. However, these results must he confirmed by a prospective controlled trial.

KW - Corticosteroids

KW - Immunosuppressive therapy

KW - Nephritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0031953377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031953377&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 681

EP - 686

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -